Short Interest in 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Rises By 252.1%

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) was the recipient of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 51,400 shares, a growth of 252.1% from the February 28th total of 14,600 shares. Based on an average trading volume of 437,500 shares, the short-interest ratio is currently 0.1 days. Approximately 3.7% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Several analysts recently weighed in on SXTP shares. HC Wainwright reissued a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research note on Friday. Weiss Ratings reiterated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Saturday, March 22nd.

60 Degrees Pharmaceuticals Stock Performance

NASDAQ:SXTP opened at $1.86 on Friday. 60 Degrees Pharmaceuticals has a fifty-two week low of $1.41 and a fifty-two week high of $35.99. The company has a 50 day simple moving average of $2.61 and a two-hundred day simple moving average of $4.63. The company has a market capitalization of $2.74 million, a PE ratio of -0.18 and a beta of 4.52.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.